Lisa • February 28, 2023
HCMA/Nest Portal – HCMA Founder introduces you to a new way to get educated and stay engaged

We were excited to announce on HCM Awareness Day 2023 our new partnership with Nest Genomics, a provider of services that helps educate patients to achieve the best outcomes in care and shared decision-making. As the HCMA grows, we must find new ways to provide personal attention and scale up to the larger community we are serving. One of my personal challenges has been how to communicate effectively on topics that are critical to the patient journey experience, including why tests are needed, where they can be done most effectively, what these tests and procedures are, and provide these and other important items in a place you can revisit them later. Additionally, we wanted to create a way to update records effectively to prepare for navigation calls as well as provide updates on frequently asked questions, quick updates of changes in care guidelines, or educating people with new opportunities.

Nest is the KEY!

Lisa Salberg – Cheers

Here is an interview I had during HCM Awareness Day with Moran Snir, the founder/CEO of Nest Genomics. We review our goal for the Nest portal and how we work together.

More answers: Nest FAQ

I hope you are as excited about this new tool in our toolbox to help support you and the HCM community. Together, we can make things better for the diagnosed, find the undiagnosed, help with new treatment options, and learn together to save lives.

We are rolling it out in stages, so please be patient as we launch, but when we reach you, please don’t let our invitation to participate sit too long. We need to help over 10,000 people have their turn to join us in the HCMA Nest Portal. If you have questions, don’t hesitate to get in touch with our office: pm@4hcm.org

HCMA Blog

By Erica Friedman June 26, 2025
Investigative journalists Debbie Cenziper, Megan Rose, Brandon Roberts and Irena Hwang from Pro Publica and NPR have concluded a 14-month long investigation into the quality of generic drugs coming into the United States from overseas. Among the many voices that spoke up for American patients was HCMA Founder and CEO, Lisa Salberg who has felt the effects of low-quality drugs personally. Salberg believes that fixing this problem is something we can do, even in this time, when even health care is highly politicized. Read the key takeaways from ProPublica’s 14-month investigation into the FDA’s oversight of foreign drugmakers in Threat in Your Medicine Cabinet: The FDA’s Gamble on America’s Drugs .
A light blue and dark blue paintbrush stroke intersect to make a stylized
By Erica Friedman June 18, 2025
Alnylam press release on the European Commission approval of AMVUTTRA® (vutrisiran) forwild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM) as an additional indication
Light & dark blue brush stroke that intersect create an abstract letter 'a' next to the word Alnylam
By Erica Friedman June 17, 2025
AMVUTTRA® (vutrisiran) has been approved by the U.S. Food and Drug Administration (FDA) to treat ATTR-CM in adults.
More Posts